In a murine model of severe, steroid-resistant asthma, the administration of either a neutralizing anti-IL-1β antibody or a pharmacological NLRP3 inhibitor (MCC950) suppressed lung IL-1β production and neutrophilic airway inflammation [111]. This evidence concerns the gene IL1B and asthma.